Recruitment

Recruitment Status
Completed
Estimated Enrollment
92

Exclusion Criteria

Prior exposure to approved or experimental HCV Protease Inhibitors
Presence of cirrhosis
Co-infection with HIV or hepatitis B virus (HBV)
...
Prior exposure to approved or experimental HCV Protease Inhibitors
Presence of cirrhosis
Co-infection with HIV or hepatitis B virus (HBV)
History of clinically significant illness or any other medical disorder that may interfere with participant's treatment, assessment or compliance with the protocol
Current or prior history of clinical hepatic decompensation
Chronic use of systemic immunosuppressive agents
Pregnant or nursing female or male with pregnant female partner

Summary

Conditions
Hepatitis C Virus Infection
Type
Interventional
Phase
Phase 1
Design
  • Allocation: Randomized
  • Intervention Model: Parallel Assignment
  • Masking: Double (Participant, Investigator)
  • Primary Purpose: Treatment

Participation Requirements

Age
Between 18 years and 65 years
Gender
Both males and females

Exclusion Criteria

Prior exposure to approved or experimental HCV Protease Inhibitors
Presence of cirrhosis
Co-infection with HIV or hepatitis B virus (HBV)
...
Prior exposure to approved or experimental HCV Protease Inhibitors
Presence of cirrhosis
Co-infection with HIV or hepatitis B virus (HBV)
History of clinically significant illness or any other medical disorder that may interfere with participant's treatment, assessment or compliance with the protocol
Current or prior history of clinical hepatic decompensation
Chronic use of systemic immunosuppressive agents
Pregnant or nursing female or male with pregnant female partner

Tracking Information

NCT #
NCT02185794
Collaborators
Not Provided
Investigators
Study Director: Gilead Study Director Gilead Sciences